Trial
NCT06984328
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genmab
Collaborators
—
Condition
Cutaneous Melanoma
Intervention
Acasunlimab
Why stopped
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11